NCT02437916 - Safety Study of AMG 228 to Treat Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 21, 2015

Primary Completion Date

December 12, 2016

Study Completion Date

December 12, 2016

Conditions

Advanced MalignancyAdvanced Solid TumorsCancerOncologyOncology PatientsTumorsMelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckTransitional Cell Carinoma of BladderColorectal Cancer

Interventions

DRUG

AMG 228

AMG 228 will be administered intravenously

Trial Locations (7)

3000

Research Site, Leuven

3050

Research Site, Parkville

10032

Research Site, New York

69120

Research Site, Heidelberg

92093

Research Site, La Jolla

94805

Research Site, Villejuif

06520

Research Site, New Haven